

(51) International Patent Classification:

A61K 47/54 (2017.01) A61P 13/12 (2006.01)
C07K 16/44 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:

PCT/US2024/026733

(22) International Filing Date:

29 April 2024 (29.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/499,231	29 April 2023 (29.04.2023)	US
63/504,877	30 May 2023 (30.05.2023)	US
63/604,935	01 December 2023 (01.12.2023)	US
63/623,279	21 January 2024 (21.01.2024)	US
63/567,174	19 March 2024 (19.03.2024)	US


(71) Applicant: **BIOHAVEN THERAPEUTICS LTD.**
[US/GB]; Ritter House, P.O. BOX 173, Road Town, Torto-
la, VG1110 (VG).

(72) Inventors: **DUBOWCHIK, Gene M.**; Biohaven Pharma-
ceuticals, Inc., 215 Church Street, New Haven, Connecti-
cut 06510 (US). **VAILL, Ada**; Biohaven Pharmaceuticals,
Inc., 215 Church Street, New Haven, Connecticut 06510
(US). **CALDWELL, Reese M.**; Biohaven Pharmaceuti-
cals, Inc., 215 Church Street, New Haven, Connecticut
06510 (US). **LINHARES, Brian**; Biohaven Pharmaceu-
ticals, Inc., 215 Church Street, New Haven, Connecticut
06510 (US). **LEAHY, David K.**; Biohaven Pharmaceu-
ticals, Inc., 215 Church Street, New Haven, Connecticut
06510 (US). **BRYSON, James**; Biohaven Pharmaceuticals,
Inc., 215 Church Street, New Haven, Connecticut 06510
(US). **MARCIN, Lawrence R.**; Biohaven Pharmaceuticals,
Inc., 215 Church Street, New Haven, Connecticut 06510
(US).

(74) Agent: **ZUEV, Dmitry**; Biohaven Pharmaceuticals, Inc.,
215 Church Street, New Haven, Connecticut 06510 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

(54) Title: BIFUNCTIONAL DEGRADERS OF GALACTOSE-DEFICIENT IMMUNOGLOBULINS



(57) Abstract: A composition of matter including a deglycosylated IgA-binding moiety, a cellular receptor-binding moiety that binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting deglycosylated IgA-binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing galactose-deficient IgA1 in a patient or subject.

[Continued on next page]

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*